Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406200 | 0.85 | MEN1 (0.54) | MEN1KMT2AHRH4NPY5RPRKDC | |
| SCHEMBL5395227 | 0.84 | MEN1 (0.56) | MEN1KMT2AHRH4NPY5RPRKDC | |
| SCHEMBL5412125 | 0.82 | MEN1 (0.60) | MEN1KMT2AMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL5491482 | 0.82 | MEN1 (0.60) | MEN1KMT2AMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL10817740 | 0.81 | KDM4E (0.51) | MAPK1HSD17B10L3MBTL1HRH4PIK3CA | |
| SCHEMBL22911885 | 0.81 | NPY5R (0.47) | MEN1KMT2AHRH4NPY5RPIK3CA | |
| SCHEMBL28730064 | 0.81 | HRH4 (0.46) | MEN1KMT2AHRH4PIK3CA | |
| SCHEMBL22911951 | 0.81 | HRH4 (0.46) | MEN1KMT2AHRH4PIK3CA | |
| SCHEMBL5403899 | 0.81 | MEN1 (0.62) | MEN1KMT2AMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL5400137 | 0.81 | MEN1 (0.62) | MEN1KMT2AMAPK1HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205309-B2 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | claimed |
| EP-1560816-A1 | QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-10 | — | — | EP | claimed |
| US-20040029901-A1 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-12 | — | — | US | claimed |
| WO-2004005265-A1 | QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-15 | — | — | WO | claimed |
| US-20220388990-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2021011796-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-7205309-B2 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1560816-A1 | QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-10 | — | — | EP | disclosed |
| US-20040029901-A1 | Quinazoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2004005265-A1 | QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029901-A1 | Quinazoline derivatives | GPR119, NQO2, CYP7A1 | MEN1 1326/4885KMT2A 1664/4885MAPK1 1442/4885 |
| US-20220388990-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK2, CCNK, CDK1 | MEN1 2487/4885KMT2A 985/4885MAPK1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.